Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease

Kramer, Hans‐Heiner; Sommer, Michael; Rammos, S.; Krogmann, Otto N.

doi:10.1007/bf02276712

Cited by 51 publications

(20 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We assumed that the absence of significance might be related to low number of study group. On the other hand, incidence of apnea is noted in approximately 12 %, generally in early stages of therapy particularly in low-birth-weight babies [1,4,6,7]. The incidence and timing of apnea were similar in our study.…”

Section: Discussionsupporting

confidence: 68%

“…The incidence and timing of apnea were similar in our study. Various studies have reported that prostaglandin E1-dependant side effects generally needed no comprehensive intervention, and discontinuation of the therapy is generally not needed [1,[3][4][5][6][7][8][9]. In our practice, all side effects were manageable, and therapy was not discontinued due to side effects.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease

et al. 2015

View full text Add to dashboard Cite

Prostaglandin E1 is crucial for keeping the patent ductus arteriosus in critical congenital heart disease for the survival and palliation of particularly prematurely born babies until a cardiosurgical intervention is available. In this study, the side effects of prostaglandin E1 in newborns with critical congenital heart disease and clinical outcomes were evaluated. Thirty-five newborns diagnosed with critical congenital heart disease were treated with prostaglandin E1 between January 2012 and September 2014 at our hospital. Patient charts were examined for prostaglandin E1 side effects (metabolic, gastric outlet obstruction, apnea), clinical status, and prognosis. Acquired data were analyzed in the SPSS 20.0 program. Patients with birth weight under 2500 g needed more days of prostaglandin E1 infusion than ones with birthweight over 2500 g (P = 0.016). The ratio of patients with birth weight under 2500 g who received prostaglandin E1 longer than 7 days was higher than the patients with birth weight over 2500 g (P = 0.02). Eighteen side effects were encountered in 11 of 35 patients (31%). Of these side effects, 1 patient had 4, 4 patients had 2, and 6 patients had only 1 side effect. Discontinuation of the therapy was never needed. Prostaglandin E1 is an accepted therapy modality for survival and outcome in critical congenital heart disease in particularly low-birth-weight babies until a surgical intervention is available. Side effects are not less encountered but are almost always manageable, and discontinuation is not needed.

show abstract

Section: Discussionsupporting

confidence: 68%

Section: Discussionmentioning

confidence: 88%

Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In ductus-dependent congenital heart disease, preserving the blood flow through the DA is essential for the infant's survival, before surgery. To maintain it open, prostaglandins are very effective, particularly since they are administered shortly after birth [3]. However, prostaglandin treatment entails certain difficulties.…”

Section: Introductionmentioning

confidence: 99%

Ductal closure and near-infrared spectroscopy for regional oxygenation monitoring in ductus-dependent congenital heart disease

Séguéla

Guillet

Thambo

et al. 2015

Archives de Pédiatrie

View full text Add to dashboard Cite

“…26 For patients in shock with suspected ductal closure or a restrictive ductus arteriosus, the initial prostaglandin dose is 0.05 to 0.1 µg/kg per minute; once ductal patency is achieved, the infusion can be decreased to an effective dose of 0.01 to 0.02 µg/kg per minute. 27 Using the lowest effective prostaglandin dose to maintain ductal patency is important to minimize the most common dose-dependent side effects of the medication. Hypotension requiring volume replacement and respiratory depression requiring mechanical ventilation may occur.…”

Section: Vasoactive Infusions and Inotropesmentioning

confidence: 99%

Preoperative Stabilization of Infants With Hypoplastic Left Heart Syndrome Before Stage I Palliation

Donnellan

Justice

2016

Critical Care Nurse

View full text Add to dashboard Cite

Hypoplastic left heart syndrome is a severe form of congenital heart disease that results in single-ventricle physiology. Although surgical palliation in infants with this syndrome is widely agreed on in practice, variation occurs in both surgical and medical management. Perinatal factors that affect preoperative management include the subtype of the syndrome and the patient's birth weight, gestational age, and genetic abnormalities. The general aspects of perioperative stabilization and management are monitoring, use of vasoactive infusions, ventilatory support, and nutrition. Management strategies for balancing single-ventricle physiology are aimed at addressing the 3 major causes of desaturation: diminished pulmonary blood flow, low mixed venous oxygen saturation, and pulmonary venous desaturation. (Critical Care Nurse. 2016; 36[1]:52-59)

show abstract

Evaluation of low dose prostaglandin E1 treatment for ductus dependent congenital heart disease

Abstract: PGE1 can be successfully administered in lower doses than previously recommended. Especially high initial doses can be avoided and low maintenance doses allow long-term treatment without serious complications.

Cited by 51 publications

References 19 publications

Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease

Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease

Ductal closure and near-infrared spectroscopy for regional oxygenation monitoring in ductus-dependent congenital heart disease

Preoperative Stabilization of Infants With Hypoplastic Left Heart Syndrome Before Stage I Palliation

Contact Info

Product

Resources

About